PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 22, 2026Journal of Translational Medicine1 citationsOpen Access

Mesenchymal stem/stromal cell-based therapies for autism spectrum disorder: emerging evidence and clinical prospects

MXMinghui XuXZXiaohan ZhangYLYuqian Liu

Key Points

  • This review aims to evaluate the potential of mesenchymal stem cell-based therapies for autism spectrum disorder.
  • Comprehensive review of preclinical evidence from various ASD animal models (2015-2025).
  • Analysis of registered early-phase clinical trials (Phase I and II) focusing on MSC therapies for ASD.
  • Comparison of different MSC sources, safety profiles, and preliminary efficacy outcomes.
  • Preclinical studies show improvements in social behavior, repetitive actions, and cognitive function following MSC administration.
  • Safety profiles from initial clinical trials indicate potential for MSC therapies in ASD.
  • Challenges include trial design heterogeneity, small sample sizes, and the need for more rigorous studies.

Abstract

Autism spectrum disorder (ASD) is a complex neurodevelopmental condition with rising global prevalence. Current management strategies predominantly address behavioral symptoms rather than core neurobiological dysfunctions, highlighting an unmet need for mechanism-targeted interventions. This review comprehensively evaluates the therapeutic potential of mesenchymal stem/stromal cell (MSC)-based therapies for ASD. We discuss the multi-faceted mechanisms through which MSCs and their secretomes (particularly MSC-EVs or MSC-exos) may ameliorate ASD pathophysiology, including modulation of neuroinflammation via anti-inflammatory cytokine and adenosine signaling, promotion of neurogenesis and synaptic plasticity through neurotrophic factors (e.g., BDNF, GDNF), restoration of gut-brain axis communication, and enhancement of cerebral angiogenesis via VEGF. We synthesize a decade of preclinical evidence (2015–2025) from various ASD animal models (e.g., BTBR, VPA-induced, MIA, Shank3B KO), detailing improvements in social behavior, repetitive actions, and cognitive function following MSC or MSC-derived product administration via routes such as intravenous, intranasal, or intracerebroventricular delivery. Furthermore, we analyze all registered early-phase clinical trials (Phase I and II, n = 9 as of March 2026), comparing different MSC sources, their safety profiles, and preliminary efficacy outcomes. Key challenges are examined, including heterogeneity in trial design, small sample sizes, the predominance of open-label studies, and the gap between promising preclinical results and established clinical translation. MSC-based therapy represents a transformative, pathophysiology-informed strategy for ASD. While preclinical and early clinical data are encouraging, significant hurdles remain in standardization, dose optimization, and demonstration of long-term efficacy and safety. We emphasize the necessity for rigorous, large-scale randomized controlled trials (RCTs) to advance this promising therapeutic approach toward clinical application.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Xu et al. (2026) studied this question.

synapsesocial.com/papers/69bf8641f665edcd009e8d3ehttps://doi.org/10.1186/s12967-026-08030-3
Ask AI
Helpful
Bookmark
Share
View Full Paper